(Q39367173)

English

Pre-existing Fas ligand (FasL) in cancer cells elicits tumor-specific protective immunity, but delayed induction of FasL expression after inoculation facilitates tumor formation

scientific article published on 9 April 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Pre-existing Fas ligand (FasL) in cancer cells elicits tumor-specific protective immunity, but delayed induction of FasL expression after inoculation facilitates tumor formation (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

Hsiao-Ying Chiu

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Guang-Huan Sun

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Shiow-Yi Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Hsiao-Hsien Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ming-Yi Ho

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Chia-Yi Chu

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Wan-Lin Wu

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ren-Shiang Jhou

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yi-Lin Tsai

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Rui-Ting Huang

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Kuang-Hui Sun

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Shye-Jye Tang

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

9 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Molecular Carcinogenesis

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

52

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

705-714

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Fas ligand-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

CD95 promotes tumour growth

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Breast cancer stem cells, cytokine networks, and the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Co-evolution of tumor cells and their microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

The immunoregulatory mechanisms of carcinoma for its survival and development

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Expression of Fas ligand by microglia: possible role in glioma immune evasion

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

The Fas signalling pathway and its role in the pathogenesis of cancer

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Proinflammatory consequences of transgenic fas ligand expression in the heart

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Regulation of the proinflammatory effects of Fas ligand (CD95L).

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Tumor-driven evolution of immunosuppressive networks during malignant progression

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

The effects of FasL on inflammation and tumor survival are dependent on its expression levels.

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

A role for CD95 ligand in preventing graft rejection

1 reference

https://api.crossref.org/works/10.1002%2FMC.21909

21 January 2018

Identifiers

10.1002/MC.21909

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39367173&oldid=1823099836"